Temporomandibular Disorder
Conditions
Interventions
Participants will be distributed in 4 groups, with 25 patients per group. Group 1 (control SHAM) consists of 25 patients who will receive guidance on self-control for pain in TMD, twice a week and wil
Other
E02.774
E07.632.490
F02.784.176
Sponsors
Faculdade de Odontologia da Universidade de São Paulo
Faculdade de Odontologia da Universidade de São Paulo
Eligibility
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Participants aged between 18 and 55 years; diagnosed with myalgia and arthralgia, with or without disc displacement; reporting pain or discomfort related to the TMJ area, greater than 4 cm in a visual analogic scale; literated.
Exclusion criteria
Exclusion criteria: Participants that carry muco-supported dental prostheses, orthopedic or orthodontic appliances; whose state of health contraindicates some of the therapies; who present teeth in severe precarious conditions, as an indication of endodontic treatment; carriers of rheumatoid arthritis; who are using any analgesic or antiinflammatory medication; carriers of congenital problems with involvement of TMJ or orofacial and cervical skull region; with recent mandibular fractures; or pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in pain intensity according to a visual analogue scale of 10 cm at each stage of treatment evaluation (initial, immediately after first session, end of treatment, 30-day control). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome 1 - difference in extension of mandibular movements such as opening, right lateral, left lateral and protrusion measured in miliiters with a digital caliper at each stage of treatment evaluation (initial, immediately after the first session, end of treatment, 30-day control ).;Secondary outcome 2 - difference in pressure pain threshold on the lateral of TMJ, anterior temporalis and superficial masseter muscles bilaterally measured with an algometer (FDX 25, Pain Test, Wagner Instruments, USA) at each stage of treatment evaluation (initial, immediate after the first session, end of treatment, 30-day control).;Secondary outcome 3 - difference in overall quality of life measured with the SF-36 questionnaire at each stage of treatment evaluation (initial, immediately after the first session, end of treatment, 30-day control).;Secondary outcome 4 - difference in quality of life related to oral health measured with the OHIP-14 questionnaire at each stage of treatment evaluation (initial, immediately after the first session, end of treatment, 30-day control).;Secondary outcome 5 - difference in patient's perspiration regarding their limitation of mandibular function measured with the MFIQ questionnaire at each stage of treatment evaluation (initial, immediately after the first session, end of treatment, 30-day control). | — |
Countries
Brazil
Contacts
Public ContactSolange de Fantini
Faculdade de Odontologia da Universidade de São Paulo
Outcome results
None listed